Skip to main content

Table 1 Response and time to progression in randomized trials comparing aromatase inhibitors and tamoxifen as neoadjuvant therapy or in advanced breast cancer

From: Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens

Reference Agent administered Number of subjects Response(%) Clinical benefit(%) Time to progression(months)
[9] Letrozole 453 30 49 9.4
  Tamoxifen 454 20 38 6.0
[13] Letrozole 154 55 - -
  Tamoxifen 170 36 - -
[11] Anastrozole 171 21 59 11.1
  Tamoxifen 182 17 46 5.6
[19] Anastrozole 340 33 56 8.2
  Tamoxifen 328 33 56 8.3
[11] Anastrozole 121 43 83 -
  Tamoxifen 117 31 56 -
[10] Exemestane 61 41 57 -
  Tamoxifen 59 17 42 -